Table 1.

Isoflavone intake and breast cancer risk in high-consuming populations

Authors [Ref.]	Study design	Subjects, n	Results (95% CI)	Comments
Wu et al. [35]	meta-analysis of 8 studies (7 case-control, 1 cohort)	3,493 cases, 5,421 controls; cohort of 21,852 women	OR 0.71 (0.60–0.85)	≥ 20 mg vs. ≤ 5 mg daily isoflavone intake
Wu et al. [36]	cohort study	629 cases; cohort of 35,303 women	RR 0.82 (0.70–0.97)	>10.6mg/1,000kcal vs. ≤ 10.6 mg/1,000 kcal intake of daily isoflavones
Iwasaki et al. [37]	nested case-control study	144 cases, 288 controls out of 24,226 women	OR 0.34 (0.16–0.74)	highest vs. lowest quartile of serum levels of genistein; no difference for daidzein serum levels and no significant difference for dietary isoflavone intake
Lampe et al. [38]	case-control study	196 cases, 1,002 controls	OR 0.26 (0.13–0.50)	highest vs. lowest quartile of plasma levels of genistein

CI = Confidence interval; OR = odds ratio; RR = risk ratio.